The formulation provides greater dosing flexibility, including administration with or without food or water and compatibility with proton pump inhibitors (PPIs) and H₂ receptor antagonists (H₂RAs) without timing restrictions.
The launch represents an important milestone in Flex Pharma’s vision to develop innovative, next-generation formulations of complex oncology medicines that significantly improve patient outcomes.
Read the full announcement from Cycle Pharmaceuticals to learn more about CAVHANZA™ and its U.S. launch: Cycle Pharmaceuticals Launches CAVHANZA™ in the United States